-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inflammatory bowel disease (IBD) is a chronic inflammatory disease that includes two main esopathic types: Crohn's disease (CD) and ulcerative colitis (UC).
incidence of IBD is increasing globally, higher in Western countries, but appears to be growing fastest among newly industrialized countries.
It is well known that long-term intestinal inflammation in IBD patients leads to a higher incidence of colorectal cancer (CRC) than in the general population, and colorectal cancer appears to be more aggressive in IBD patients, who have higher mortality rates than those without IBD.
, CRC in IBD tends to be earlier and more likely to be multi-lying.
, although biologics are becoming more common in IBD patients, their effects on colorectal cancer remain unclear.
study aims to describe the effects of biologics on CRC in IBD patients by using a large database.
researchers conducted retrospective studies of patients in electronic databases at several U.S. hospitals from 1999 to 2020.
included patients identified as IBD in this study and then conducted a multivariate analysis to adjust for a variety of factors, including medications and surgical therapies, to observe the effects of biologics on CRC in IBD patients.
between 1999 and 2020, there were 6,207,510 patients in the database.
, 225090 (0.36%) had Crohn's disease, while 188420 (0.30%) had ulcerative colitis.
patients with IBD were more likely to develop CRC after adjusting for mixing factors using multi-factor analysis.
IBD population, patients treated with anti-TNF drugs were less likely to develop CRC.
crohn's disease (OR 0.69; 95% confidence interval 0.66-0.73); Patients with ulcerative colitis (OR: 0.78; 95% confidence interval 0.73-0.83; P<0.0001).
IBD patients treated with anti-tumor necrotics are less likely to develop CRC, the researchers concluded.
may provide protective effects with biologics in IBD patients through inflammation control and mucosa healing.
.
